Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Insights into MRSA Epidemic

Published: Wednesday, May 02, 2012
Last Updated: Wednesday, May 02, 2012
Bookmark and Share
Scientists identify a gene playing a pivotal role in epidemic waves of MRSA infections in Asia.

NIH scientists and their colleagues in China have identified a gene that’s been playing a pivotal role in epidemic waves of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia. The finding suggests a potential target for novel therapeutics.

Decades ago, doctors used penicillin to treat people infected with the S. aureus bacterium, commonly known as staph. When S. aureus developed resistance to the antibiotic, doctors turned to methicillin.

In 1961, scientists identified the first strains of S. aureus bacteria that resisted methicillin. MRSA is now a leading cause of severe infections in hospitals.

Since bacteria inherit identical copies of their mother cell's genes, lineages are referred to as clones. MRSA epidemics occur in waves, with old clones of MRSA bacteria disappearing and new clones emerging.

A limited number of MRSA clones are responsible for most MRSA infections worldwide.

In China and large parts of Asia, ST239 is the predominant MRSA lineage. Recently, genome sequencing of ST239 revealed a rare new gene.

A research team led by Dr. Michael Otto of NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Dr. Yuan Lu of Fudan University in Shanghai set out to study whether the new gene, which they called sasX, might play a role in the spread of MRSA in China.

The researchers analyzed 807 patient samples of invasive S. aureus taken over the past decade from 3 Chinese hospitals.

In the early online edition of Nature Medicine on April 22, 2012, they reported that sasX is more prevalent in MRSA strains from China than previously thought.

They found that the gene's frequency is also increasing: From 2003 to 2011, the percentage of MRSA samples containing sasX almost doubled, from 21% to 39%.

Most of the sasX-positive samples in the study were from ST239. However, while sasX was found almost exclusively among ST239 strains early in the study, its frequency among other clonal types increased considerably since then, from 5% in 2003-2005 to 28% in 2009-2011.

This supports a long-held theory that new clones of virulent MRSA arise through the exchange of DNA between different strains. Indeed, the sasX gene is embedded in a so-called mobile genetic element, a DNA segment that can transfer easily between strains.

The researchers next explored the biological role of sasX. They found that the protein coded by sasX appears at the S. aureus cell surface.

A series of laboratory and mouse studies showed that sasX helps the bacteria to colonize the nose and cause skin abscesses and lung disease. The protein also helps the bacteria evade human immune defenses.

Taken together, these findings establish sasX as a crucial factor in MRSA's virulence and a probable driving force of the Asian MRSA epidemic. “This research helps us understand how new, more dangerous forms of MRSA can keep appearing,” Otto says.

Based on their observations, the researchers predict that sasX is likely to continue to spread. They plan to keep monitoring its progress. They're also working to develop therapeutics against MRSA strains that express sasX.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Thursday, August 27, 2015
Large Percentage of Youth with HIV May Lack Immunity to Measles, Mumps, Rubella
NIH study finds those vaccinated before starting modern HIV therapy may be at risk.
Tuesday, August 18, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
Douglas Lowy Named Acting Director of the National Cancer Institute
Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth.
Tuesday, April 07, 2015
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Thursday, April 02, 2015
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
Friday, March 27, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
Tuesday, February 03, 2015
NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
Results from NIH Phase 1 clinical trial support accelerated development of candidate vaccine.
Friday, November 28, 2014
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Thursday, October 23, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
NIH and FDA Win Top National Award
Award for intellectual property licensing of meningitis vaccine.
Saturday, September 27, 2014
Scientific News
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos